Marc Casper
Marc Newton Casper (born c. 1967) is an American business executive who serves as the Chairman, President, and Chief Executive Officer of Thermo Fisher Scientific, the world's largest provider of scientific instrumentation, reagents, consumables, software, and services to healthcare, life science, and research customers. Under his leadership since 2009, Thermo Fisher has grown into a $225+ billion market capitalization company with approximately $43 billion in annual revenue and over 100,000 employees worldwide.
Casper played a critical role during the COVID-19 pandemic, as Thermo Fisher's diagnostic testing, research tools, and vaccine/therapy production capabilities became essential to the global pandemic response. The company generated approximately $15+ billion in cumulative pandemic-related revenue during 2020-2024, supporting COVID-19 testing, vaccine development, and therapeutics manufacturing before this revenue wound down in late 2024 and 2025.
A graduate of Wesleyan University and Harvard Business School, Casper built his career in management consulting at Bain & Company and Bain Capital before transitioning to operational leadership in the life sciences industry. He joined Thermo Fisher's predecessor company in 2001 and rose through executive ranks to become CEO in 2009 and Chairman in 2020.
Casper is married to Denise J. Casper, a United States district court judge and the first Black female judge to serve on the federal bench in Massachusetts. Judge Casper notably presided over the criminal trial of Whitey Bulger. The couple has twin sons.
Early life and education
Marc Newton Casper was born around 1967 in the United States. Limited public information is available about his early life and family background.
Wesleyan University
Casper attended Wesleyan University in Middletown, Connecticut, where he earned a bachelor's degree in economics. Wesleyan is a selective private liberal arts university known for producing graduates in business, academia, and the arts.
His connection to Wesleyan has remained strong throughout his career. He currently serves as a trustee of the university, contributing to its governance and strategic direction. However, his board service has also drawn controversy from student activists concerned about Thermo Fisher's business practices in China.
Harvard Business School
After working in management consulting for several years, Casper enrolled at Harvard Business School, where he earned his MBA with Honors. The Harvard MBA positioned him for senior leadership roles in corporate America and exposed him to the strategic and financial frameworks that would guide his career.
He continues his affiliation with Harvard as a member of the Board of Dean's Advisors at Harvard Business School, advising on the school's strategic priorities.
Career
Management consulting (early career)
Casper began his professional career as a strategy consultant at Bain & Company, one of the world's premier management consulting firms. The role exposed him to a wide range of industries and business challenges, developing analytical and problem-solving skills.
He subsequently joined Bain Capital, the private equity firm co-founded by Mitt Romney that spun off from Bain & Company. At Bain Capital, Casper gained experience evaluating investment opportunities and working with portfolio companies on operational improvements.
Early life sciences career
Casper transitioned from consulting to operational roles in the life sciences industry:
Dade Behring: He served as President-Americas at Dade Behring Inc., a clinical diagnostics provider that was later acquired by Siemens. The role gave him experience running a major segment of a healthcare company.
Kendro Laboratory Products: Before joining Thermo Fisher, Casper served as President, Chief Executive Officer, and Director of Kendro Laboratory Products, a laboratory equipment company. This CEO experience prepared him for leading a larger organization.
Thermo Fisher Scientific (2001-present)
Rise through the organization (2001-2009)
In 2001, Casper joined Thermo Electron Corporation as Vice President of the Life Sciences sector. He had identified the life sciences industry as an area of significant growth potential and was attracted by the opportunity to build businesses serving researchers and healthcare customers.
He was promoted to Senior Vice President in 2003, taking on broader responsibilities. In 2005, he assumed responsibility for all of the company's operating divisions, positioning himself as a potential successor to top leadership.
In 2006, Thermo Electron merged with Fisher Scientific International in a transformative deal that created Thermo Fisher Scientific, establishing one of the largest companies in the life sciences and laboratory products industry. Following the merger, Casper was named Executive Vice President and President of the Analytical Technologies businesses.
In 2008, he was promoted to Chief Operating Officer, placing him in direct line for the CEO position.
CEO appointment (2009-present)
In October 2009, Casper was named President and Chief Executive Officer of Thermo Fisher Scientific, succeeding Marijn Dekkers. At the time, Thermo Fisher had approximately $10 billion in annual revenue - a fraction of its current size.
Under Casper's leadership, Thermo Fisher has pursued an aggressive acquisition-driven growth strategy combined with organic expansion:
Key acquisitions:
- Life Technologies (2014) - $13.6 billion, adding genetic analysis and cell biology capabilities
- Patheon (2017) - $7.2 billion, expanding pharmaceutical services
- PPD (2021) - $17.4 billion, adding clinical research services
- Numerous smaller acquisitions in diagnostics, instruments, and services
Financial growth (2009-2024):
- Revenue growth from ~$10 billion to ~$43 billion
- Market capitalization growth to over $225 billion
- Share price appreciation of over 800%
- Consistent dividend growth
Chairman appointment (2020)
In February 2020, Thermo Fisher's board elected Casper as Chairman, consolidating leadership of the company. The combined Chairman and CEO role gave him full authority over Thermo Fisher's strategic direction at a pivotal moment - just weeks before the COVID-19 pandemic would dramatically increase demand for the company's products.
COVID-19 pandemic response
Thermo Fisher played a critical role in the global response to the COVID-19 pandemic:
Diagnostic testing: The company's diagnostic instruments, reagents, and testing kits were essential for COVID-19 testing worldwide. Thermo Fisher ramped up production dramatically to meet unprecedented demand.
Vaccine and therapy development: Thermo Fisher's cell culture media, purification systems, and other bioproduction tools were used by pharmaceutical companies developing COVID-19 vaccines and therapeutics, including mRNA vaccine manufacturers.
Research tools: Scientists studying the SARS-CoV-2 virus relied on Thermo Fisher's sequencing, PCR, and other research technologies.
The pandemic generated significant financial tailwinds:
- Cumulative pandemic-related revenue of approximately $15+ billion during 2020-2024
- Peak pandemic-related revenue of several billion dollars annually in 2021-2022
- 2024 pandemic-related revenue of $520 million (declining: ~$100 million testing, ~$420 million vaccines/therapies)
- 2025 guidance assumes essentially zero pandemic-related revenue
While the pandemic windfall was temporary, it demonstrated Thermo Fisher's essential role in scientific and healthcare infrastructure.
Recent performance (2024-2025)
As pandemic-related revenue wound down, Thermo Fisher focused on its core growth drivers:
Full Year 2024:
- Revenue: $42.88 billion (flat year-over-year)
- Q4 revenue growth: 5% to $11.4 billion
- Adjusted EPS: $21.86
- Capital returned to shareholders: $4.6 billion (buybacks and dividends)
2025 Guidance:
- Revenue: $43.5-$44 billion (3-4% organic growth)
- Adjusted EPS: $23.10-$23.50 (6-8% growth)
- Headwind of ~1% from remaining pandemic revenue runoff
The company continues to invest in high-growth areas including genetic analysis, pharmaceutical services, and laboratory automation.
Personal life
Marriage to Denise J. Casper
In 1994, Marc Casper married Denise Jefferson Casper, who would later become a distinguished federal judge. Judge Casper is an attorney who serves as the Chief United States District Judge for the District of Massachusetts.
Denise J. Casper made history as the first Black female judge to serve on the federal bench in Massachusetts. She was nominated by President Barack Obama in 2010 and confirmed by the Senate. Her appointment represented a milestone for diversity in the federal judiciary.
Judge Casper gained national prominence when she presided over the 2013 criminal trial of Whitey Bulger, the notorious Boston crime boss. Her handling of the high-profile case was widely praised; observers described her as "cool, calm, and collected" despite the intense media attention and courtroom drama.
The marriage connects two highly accomplished individuals in very different spheres - corporate business and the federal judiciary. It is relatively unusual for a Fortune 500 CEO to be married to a sitting federal judge.
Children
Marc and Denise Casper have twin sons. Limited public information is available about their children, reflecting the family's preference for privacy.
Residence
The Casper family resides in Massachusetts, convenient to Thermo Fisher's headquarters in Waltham, Massachusetts.
Controversies
China DNA testing and human rights concerns
Thermo Fisher has faced criticism from human rights groups and activists regarding sales of its DNA testing products to police forces in China, particularly in Tibet and Xinjiang.
The company sells Huaxia PCR DNA tests, which activists allege have been used by Chinese authorities for population surveillance and social control over Tibetan and Uyghur minorities. Critics argue that such surveillance technology could facilitate human rights abuses.
Tibetan activists have specifically targeted Casper in campaigns urging Thermo Fisher to stop selling DNA testing products to Chinese police forces. Some activists have protested at shareholder meetings and other company events.
The controversy intensified at Wesleyan University, where Casper serves as a trustee. Student activists at Wesleyan have called for his removal from the board, arguing that the university should not associate with an executive whose company allegedly facilitates human rights violations.
Thermo Fisher has stated that it does not sell products for human rights surveillance and has implemented compliance measures. However, critics argue that these assurances are insufficient given the nature of the Chinese government's documented surveillance programs in Tibet and Xinjiang.
Executive compensation
Casper's compensation has drawn attention given its scale:
2024 compensation: Approximately $30.45 million total, including:
- Base salary: $1.74 million
- Stock awards: $8.19 million
- Stock options: $14.47 million
- Bonus: $5.51 million
- Other: $537,000
The AFL-CIO and other labor organizations have highlighted CEO-to-median-worker pay ratios at Thermo Fisher as examples of growing income inequality.
Net worth
Casper's net worth is estimated at $70-650 million, with wide variation depending on the source and methodology:
Conservative estimate: Approximately $70 million based on disclosed Thermo Fisher stock holdings of 146,000+ shares valued at current prices, plus smaller positions in other companies where he has served as director.
Higher estimates: Some sources estimate his net worth at over $600 million based on cumulative stock sales, retained holdings, and other investments accumulated over his 15+ year tenure as CEO.
His ownership of approximately 146,000 Thermo Fisher shares (at roughly $490 per share as of late 2024) represents approximately $70 million in company stock alone.
Board positions and affiliations
Corporate boards:
- Thermo Fisher Scientific - Chairman, President & CEO
- Synopsys - Director
Nonprofit and academic:
- Wesleyan University - Trustee
- Mass General Brigham - Board member
- Harvard Business School Board of Dean's Advisors
- Massachusetts Math & Science Initiative - Trustee
- U.S.-China Business Council - Chairman Emeritus
Previous board positions:
- Advisory Board Company - Director
- Zimmer Holdings - Director
- U.S. Bancorp - Director
- Brigham & Women's Hospital - Director
See also
References